Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.
Witty DR, Alvaro G, Derjean D, Giblin GMP, Gunn K, Large C, Macpherson DT, Morisset V, Owen D, Palmer J, Rugiero F, Tate S, Hinckley CA, Naik H. Witty DR, et al. Among authors: giblin gmp. ACS Med Chem Lett. 2020 Jul 16;11(9):1678-1687. doi: 10.1021/acsmedchemlett.0c00263. eCollection 2020 Sep 10. ACS Med Chem Lett. 2020. PMID: 32945812 Free PMC article.
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain.
Healy MP, Allan AC, Bailey K, Billinton A, Chessell IP, Clayton NM, Giblin GMP, Kay MA, Khaznadar T, Michel AD, Naylor A, Price H, Spalding DJ, Stevens DA, Swarbrick ME, Wilson AW. Healy MP, et al. Among authors: giblin gmp. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1892-1896. doi: 10.1016/j.bmcl.2018.03.091. Epub 2018 Mar 31. Bioorg Med Chem Lett. 2018. PMID: 29636218
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; study investigators. Zakrzewska JM, et al. Among authors: giblin gm. Lancet Neurol. 2017 Apr;16(4):291-300. doi: 10.1016/S1474-4422(17)30005-4. Epub 2017 Feb 17. Lancet Neurol. 2017. PMID: 28216232 Free article. Clinical Trial.
Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist.
Sime M, Allan AC, Chapman P, Fieldhouse C, Giblin GM, Healy MP, Lambert MH, Leesnitzer LM, Lewis A, Merrihew RV, Rutter RA, Sasse R, Shearer BG, Willson TM, Xu RX, Virley DJ. Sime M, et al. Among authors: giblin gm. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5568-72. doi: 10.1016/j.bmcl.2011.06.088. Epub 2011 Jun 29. Bioorg Med Chem Lett. 2011. PMID: 21798739
Discovery of a novel series of nonacidic benzofuran EP1 receptor antagonists.
Allan AC, Billinton A, Brown SH, Chowdhury A, Eatherton AJ, Fieldhouse C, Giblin GM, Goldsmith P, Hall A, Hurst DN, Naylor A, Rawlings DA, Sime M, Scoccitti T, Theobald PJ. Allan AC, et al. Among authors: giblin gm. Bioorg Med Chem Lett. 2011 Jul 15;21(14):4343-8. doi: 10.1016/j.bmcl.2011.05.047. Epub 2011 May 23. Bioorg Med Chem Lett. 2011. PMID: 21676612
TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I, Harrison DC, Hawkins J, Chapman T, Marshall I, Facci L, Ahmed S, Brackenborough K, Skaper SD, Mead TL, Smith BB, Giblin GM, Hall A, Gonzalez MI, Richardson JC. Hussain I, et al. Among authors: giblin gm. Neurodegener Dis. 2011;8(1-2):15-24. doi: 10.1159/000313903. Epub 2010 Aug 4. Neurodegener Dis. 2011. PMID: 20689247
38 results